<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01607086</url>
  </required_header>
  <id_info>
    <org_study_id>111649</org_study_id>
    <nct_id>NCT01607086</nct_id>
  </id_info>
  <brief_title>Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo</brief_title>
  <official_title>A Randomised, Double-blind Study in Healthy Volunteers to Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this sensory analysis study is to determine whether volunteers observe a&#xD;
      significant difference in organoleptic properties between lamotrigine (430C78) cherry&#xD;
      flavoured orally disintegrating tablets (ODT) and a placebo cherry flavoured orally&#xD;
      disintegrating tablet. The aim is to assess the value of the placebo as a marketing aid,&#xD;
      whereby physicians and patients may assess the personal acceptability of the organoleptic&#xD;
      properties and potential convenience prior to prescription of the ODT formulation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2008</start_date>
  <completion_date type="Actual">July 18, 2008</completion_date>
  <primary_completion_date type="Actual">July 18, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison score of flavor and aftertaste between the active and placebo tablets.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison score of mouth feel between the active and placebo tablets</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Mental Disorders</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cherry lamotrigine ODT</intervention_name>
    <description>25mg, taken orally on one study visit</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cherry Placebo</intervention_name>
    <description>Taken orally on one study visit</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject will be eligible for inclusion in this study only if all of the following&#xD;
        criteria apply:&#xD;
&#xD;
          -  Healthy as judged by the responsible physician or designee. No clinically significant&#xD;
             abnormality identified on the medical or laboratory evaluation. A subject with a&#xD;
             clinical abnormality or laboratory parameters outside the reference range for this age&#xD;
             group may be included only if the Investigator and the Medical Monitor considers that&#xD;
             the finding will not introduce additional risk factors and will not interfere with the&#xD;
             study procedures.&#xD;
&#xD;
          -  Volunteer must have a normal sense of taste and smell&#xD;
&#xD;
          -  Non-smokers or ex-smokers who have given up smoking for at least 3 months. Subjects&#xD;
             currently using oral nicotine replacement therapy will not be recruited for this&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will not be eligible for inclusion in this study if any of the following criteria&#xD;
        apply:&#xD;
&#xD;
          -  Currently being treated for epilepsy or bipolar disorder&#xD;
&#xD;
          -  History of allergic, anaphylactic, hypersensitivity or idiosyncratic reaction(s) to&#xD;
             lamotrigine or drugs of a similar type.&#xD;
&#xD;
          -  History of sensitivity to any of the following excipients- Mannitol, Crospovidone,&#xD;
             Sucralose, Magnesium Stearate, artificial Cherry flavour, Ethylcellulose.&#xD;
&#xD;
          -  History of clinically relevant skin rashes.&#xD;
&#xD;
          -  History or presence of any medical disorder which in the view of the investigator and&#xD;
             GSK Medical Monitor makes the subject unsuitable for the study.&#xD;
&#xD;
          -  History of multiple allergies to drugs, chemicals or foods, or a history of a&#xD;
             clinically important allergy (e.g. anaphylaxis) to any one substance.&#xD;
&#xD;
          -  Currently suffering from perennial rhinitis or seasonal rhinitis, a cold, influenza or&#xD;
             any other respiratory illness.&#xD;
&#xD;
          -  Has received prescribed or non prescribed medication (including vitamins and herbal&#xD;
             remedies) within 7 days prior to the test day which in the opinion of the investigator&#xD;
             in consultation if necessary with the GSK Medical Monitor may interfere with the study&#xD;
             procedure or compromise safety.&#xD;
&#xD;
          -  Currently or recently prescribed any medication which may be affected by lamotrigine&#xD;
             including antiepileptics.&#xD;
&#xD;
          -  Participation in another sensory analysis study within 30 days preceding the test day.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days preceding the test day.&#xD;
&#xD;
          -  Females with a positive hCG pregnancy test on the test day.&#xD;
&#xD;
          -  Abuse of alcohol defined as an average weekly intake of greater than 21 units or an&#xD;
             average daily intake of greater than 3 units for men and a weekly intake of greater&#xD;
             than14 units or an average daily intake of greater than 2 units for women. [NOTE: 1&#xD;
             unit is equivalent to a half-pint (220mL) of beer or 1 (25mL) measure of spirits or 1&#xD;
             glass (125mL) of wine]. Subjects must be willing to abstain from alcohol for 24 hours&#xD;
             before each visit to the unit for the duration of the study.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period.&#xD;
&#xD;
          -  The subject has a positive drug/alcohol screen on the test day. A minimum list of&#xD;
             drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates,&#xD;
             cannabinoids and benzodiazepines.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>This study has not been published in the scientific literature.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2012</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lamotrigine</keyword>
  <keyword>placebo</keyword>
  <keyword>properties</keyword>
  <keyword>characteristics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>111649</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

